ORLANDO, Fla., Jan. 30, 2007 (PRIME NEWSWIRE) -- RedChip Visibility, a division of RedChip Companies, announced that they have initiated research on Osteologix, Inc. (OTCBB:OLGX).
Lisa Springer, MBA/CFA, RedChip Senior Research Analyst, wrote in the report:
"Osteologix's innovative new drug may offer a safer, more effective treatment of osteoporosis. In clinical trials involving specific biochemical markers of bone turnover, strontium compounds have demonstrated a unique mechanism of action, decreasing bone resorption while maintaining or accelerating the formation of new bone. According to Osteologix, no other osteoporosis product currently marketed in the U.S. has this dual effect. Equally important, studies reveal that strontium products involve none of the cancer risks or gastrointestinal side effects associated with other osteoporosis drugs.
"We are rating Osteologix's shares a 'Speculative Buy' with a one-year price target of $3.88. We believe strontium's unique uncoupling mechanism, which increases bone formation while reducing resorption, will fuel substantial sales growth for NB S101 and a ramp-up in quarterly sales comparable to what Protelos has achieved in Europe. We also believe it likely that NB S101 will capture European sales from Protelos because of the convenience of its tablet formulation and lower dosage."
To receive a complimentary copy of the RedChip Visibility initial research for OLGX, please visit: http://www.redchip.com/visibility/about.asp?page=requestOLGX_initial.
About RedChip Visibility(tm)
RedChip Research, a division of RedChip Companies Inc., writes fundamental research on small-cap companies. RedChip's success has been documented in Forbes, Barron's and the Wall Street Journal. RedChip Visibility(tm) provides small-cap companies' access to both professional and individual small-cap investors by holding conferences throughout the United States, producing online corporate visibility programs, and writing company sponsored research.
The RedChip Companies Inc. logo is available at http://www.primezone.com/newsroom/prs/?pkgid=2761
RedChip Visibility Research Disclosure
The analysts contributing to this report do not hold any shares of OLGX. Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. RedChip certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report. Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. As such, the report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed herein are subject to change. RedChip Companies Inc. is an affiliate of the Aurelius Consulting Group, Inc. Osteologix, Inc. is a client of the Aurelius Consulting Group, Inc. and of RedChip Visibility, a division of RedChip Companies. OLGX paid RedChip Visibility $32,400 for the RedChip Visibility Research Program, which includes this report.